{
    "medicine_id": "3efb72731008cecb5afaa808a1357c70492a953a",
    "platform_id": "DB01279",
    "metadata": {
        "name": "Naglazyme 1 mg ml Injection solution concentrate",
        "composition": "1 mg ml Galsulfase",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of adults and children with Mucopolysaccharidosis VI",
            "contraindications": {
                "disease": "There is no experience with overdose of galsulfase",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of GAG Mucopolysaccharidosis VI MPS VI Maroteaux Lamy syndrome is characterized by the absence or marked reduction in N acetylgalactosamine 4 sulfatase The sulfatase activity deficiency results in the accumulation of the GAG substrate dermatan sulfate throughout the body This accumulation leads to widespread cellular tissue and organ dysfunction Galsulfase is intended to provide an exogenous enzyme that will be taken up into lysosomes and increase the catabolism of GAG Galsulfase uptake by cells into lysosomes is most likely mediated by the binding of mannose 6 phosphate terminated oligosaccharide chains of galsulfase to specific mannose 6 phosphate receptors",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}